Bio-Rad Laboratories, Inc., Merck KGAA and BIOMÉRIEUX SA are dominating the Global Mycoplasma Testing In Clinical Market in 2018

Global Mycoplasma Testing in Clinical Market is expected to grow at a healthy CAGR of 12.6% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.

Access Full Report at https://databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market

Global mycoplasma testing in clinical market is an upcoming market which includes key players and local players. The market is growing owing to the favorable market scenario. The market has a prominent growth in upcoming years due to increasing R&D expenditure and technological advancements in the identification techniques. The market has witness developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of mycoplasma testing in clinical market.

For instance, In March 2019, F. Hoffmann-La Roche LTD announced launch of VENTANA DP 200 slide scanner. The product is used in pathology lab and these inventive products are able to provide high-quality images from various special stains, samples, bone marrow and cytology and frozen tissue sections.

Bio-Rad Laboratories, Inc dominated the global mycoplasma testing in clinical market. The other key players existing in the market includes are MERCK KGAA, ELITechGROUP, AB ANALITICA srl, GOLD STANDARD DIAGNOSTICS, OSANG Healthcare, BioFire Diagnostics, PromoCell GmbH, Lonza, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Liofilchem Srl, ZEAKON Diagnostics, OPERON., Sacace Biotechnologies Srl, and Seegene Inc., among others.

Bio-Rad Laboratories, Inc.:

Bio-Rad Laboratories, Inc., headquartered in California, U.S., was founded in 1952. The company focuses on providing the industry with innovative and useful products that helps life science researchers to accelerate the discovery process and medical diagnostics labs to obtain faster and better results.

  • In February 2016, Bio-Rad Laboratories, Inc. had announced CE IVD Marking for QX200 Droplet Digital PCR System. This product is used as in vitro diagnostic (IVD). Due to this there is an enhancement of product portfolio and these products can now be available in Europe market.

It has its global networks through direct sales representatives and distributors in the Americas, Asia-Pacific, Europe, Middle East and South Africa. The company also offers its product through its subsidiaries which are DiaMed Holding AG (Switzerland), QuantaLife, Inc. (U.S.), Bio-Rad AbD Serotec Limited (U.K.), GnuBIO, Inc. (U.S.), and Raindance Technologies (U.S.) among others

MERCK KGAA:

Merck KGAA headquartered in Darmstadt, Germany, and it was founded in1668. The company mainly focuses on developing, manufacturing of specified and high quality products in healthcare, life science and performance material sectors.

  • In June 2019, Merck KGAA announced partnership with Rigaku to develop novel molecular structure analysis technology. This agreement is for development of lab consumables, which uses highly innovative crystalline sponge technology. Due to this there will be increase in global presence as well as product portfolio.

It has its global networks through direct sales representatives and distributors in Asia-Pacific, Europe, North America, South America, Middle East and Africa. Its subsidiaries are Sigma-Aldrich, Millipore Sigma, Merck (Pvt) Ltd, Merck S. L. U., Merck Holding GmbH and Merck S. A. (France) among others.

BIOMÉRIEUX SA:

BIOMÉRIEUX SA headquartered in Marcy-l' Étoile, France, was founded in 1963. The company is engaged in developing In Vitro Diagnostics systems, reagents, softwares and services and is involve in microbiology testing services for treatment of various infectious diseases.

  • In November 2018, BIOMÉRIEUX SA launched a product named as the CE-Mark of the BIOFIRE FILMARRAY Pneumonia Panel plus and BIOFIRE FILMARRAY Pneumonia Panels. This Pneumonia Panel identifies 33 targets in sputum sample. With this product launch company has enhanced its product portfolio and also the product is now available in Europe market, so their revenue from Europe region could increase.

It has its global networks through direct sales representatives and distributors in North America, South America, Europe, Asia-Pacific, Oceania and Middle East & Africa. Its subsidiaries areInvisible Sentinel Inc. (France), PML Microbiologicals, Inc. (U.S.), Biomérieux Brasil S.A.(Brazil), Astute Medical, Inc.( U.S.), BTF Pty Ltd.(France) among others.